EGFR and non-small cell lung carcinoma: The third-generation EGFR-TKI osimertinib enhances both progression-free (Soria et al., 2018) and overall survival (Ramalingam et al., 2020) compared to first generation EGFR-TKIs and is now considered first-line treatment in EGFR-mutated NSCLC.